Biotech Values

[iwfal]

CYPB BioLineRx-

Results of the phase 2b EAGLE study demonstrated that CYP-1020 at the 20-30mg dose range exhibited clinically relevant and statistically significant improvement on the cognition endpoint assessed using the BACS neuropsychological test battery. The 20-30mg dose range of CYP-1020 was superior to both risperidone and placebo at endpoint on the BACS total score (p=0.027 for both), with positive trends in all subsets within the BACS.

I haven't seen any data on this endpoint, apparently the primary differentiator from existing anti-psychotics, in the 10mg dose.

If it showed a trend I'd treat this data as pretty solid. Otherwise it seems wise to be cautious.

PS I looked at all because I tend to trust Kranzler - not that every in-license is successful, but that he is adequately sceptical and kills programs that don't pan out.